VEGF: An update on biological and therapeutic aspects

Current Opinion in Biotechnology

Volumn 11, Issue 6, 2000, Pages 617-624

  Ferrara, Napoleone ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPILIN; PROTEIN TYROSINE KINASE; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ENDOTHELIUM CELL; INHIBITION KINETICS; MITOGENESIS; NONHUMAN; OSSIFICATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SWINE;

EID: 0033636357     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(00)00153-1     Document Type: Review

References (108)

1. The biology of vascular endothelial growth factor
2. Role of vascular endothelial growth factor in the regulation of angiogenesis
3. Signaling angiogenesis and lymphangiogenesis
4. Vascular endothelial growth factor is a secreted angiogenic mitogen
5. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
6. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
7. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
8. Clinical applications of angiogenic growth factors and their inhibitors
9. Vascular endothelial growth factor (VEGF) and its receptors
10. Signal relays in the VEGF system
11. Current biology of VEGF-B and VEGF-C
12. Regulation of angiogenesis via vascular endothelial growth factor receptors
13. Mechanisms of angiogenesis and arteriogenesis
14. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
15. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor
16. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells
17. Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro
18. Effects of vascular endothelial growth factor on pancreatic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro
19. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth. Enhancing cell survival and Schwann cell proliferation in the peripheral nervous system
20. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
21. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
22. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
23. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
24. VEGF regulates endothelial cell survival by the Pl3-kinase/Akt signal transduction pathway: Requirement for Flk-1/KDR activation
25. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis
26. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
27. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
28. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing
29. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing
30. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability
31. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family
32. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
33. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
34. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
35. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
36. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
37. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF
38. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis
39. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
40. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice
41. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice
42. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits VEGF-dependent Pl 3 kinase activation and endothelial cell migration
43. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
44. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: Role of flt-1
45. Neurepilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
46. Receptors for collapsin/semaphorins
47. Collapsin: A protein in brain that induces collapse and paralysis of neuronal growth cones
48. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency
49. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity
50. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: Functional competition of collapsin-1 and vascular endothelial growth factor-165
51. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4
52. Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis
53. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
54. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
55. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
56. A cardiac myocyte VEGF paracrine pathway is required to maintain cardiac function
57. VEGF is required for growth and survival in neonatal mice
58. Inducible gene targeting in mice
59. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
60. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: Autoparacrine role during endochondral bone formation
61. Conditional inactivation of VEGF-A in areas of collagen 2a1 expression results in embryonic lethality in the heterozygous state
62. The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle
63. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis
64. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis
65. Vascular endothelial growth factor is expressed in rat corpus luteum
66. Vascular endothelial growth factor messenger ribonueleic acid expression in the primate ovary
67. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally-mediated angiogenesis
68. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth
69. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade
70. Vascular endothelial growth factor is essential for corpus luteum angiogenesis
71. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody
72. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor
73. Ovarian hyperstimulation syndrome: Report of one case with notes on pathogenesis and treatment
74. Pathophysiology of the ovarian hyperstimulation syndrome
75. Vascular endothelial growth factor as a capillary permeability agent in ovarian hyperstimulation syndrome
76. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome
77. The kallikreinkinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulatton syndrome
78. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: Relevance to ovarian hyperstimulation syndrome and polycystic ovaries
79. Serum vascular endothelial growth factor levels before starting gonadotropin treatment in women who have developed moderate forms of ovarian hyperstimulation syndrome
80. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
81. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer
82. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer
83. Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome
84. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: Implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis
85. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian Steroids
86. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
87. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders
88. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis
89. Flk-1 as a target for tumor growth inhibition
90. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
91. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
92. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
93. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer
94. A phase II trial of single-agent rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelila growth factor) in patients with relapsing metastatic breast cancer
95. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer
96. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes
97. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor
98. Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen
99. VEGF antagonism reduces cerebral edema formation and tissue damage following ischemic-reperfusion injury in the mouse brain
100. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells
101. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia
102. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor: The VIVA trial
103. Review of preclinical and clinical results with vascular endothelial growth factors for therapeutic angiogenesis
104. Increased vascularization in mice overexpressing angiopoietin-1
105. Angiopoietin-1 protects the adult vasculature against plasma leakage
106. The role of angiogenesis in bone regeneration